Features Partner Sites Information LinkXpress
Sign In
Demo Company

Immobilized Lytic Enzymes Prevent Listeria Growth on Food-related Surfaces

By BiotechDaily International staff writers
Posted on 18 Apr 2013
Print article
A coating of stabilized bacteriophage lytic enzymes could prevent Listeria from surviving on equipment and packaging used in the food industry.

Listeria is a genus of bacteria, of which the most common species is Listeria monocytogenes, commonly found in soil, on unwashed vegetables, and in unpasteurized soft cheeses. These bacteria resist cold and the presence of salt and can cause food poisoning (listeriosis) with flu-like symptoms such as high fever and dizziness. While healthy individuals may not have any symptoms, those with compromised immune systems such as pregnant women, infants, and the elderly are especially at risk.

Investigators at Rensselaer Polytechnic Institute (Troy, NY, USA) previously developed a coating that could kill methicillin-resistant Staphylococcus aureus (MRSA) without antibiotics. In the present study, they observed that while a number of phage cell lytic enzymes against Listeria had been isolated, no attempt had been made to incorporate these enzymes onto surfaces.

The investigators described in the April 2, 2013, online edition of the journal Scientific Reports the development of three simple routes for the surface incorporation of the Listeria bacteriophage endolysin Ply500. These routes included covalent attachment onto [US] Food and Drugs Administration (FDA)-approved silica nanoparticles (SNPs), incorporation of SNP-Ply500 conjugates into a thin poly(hydroxyethyl methacrylate) film, and affinity binding to edible crosslinked starch nanoparticles via construction of a maltose binding protein fusion.

Testing of these coated surfaces revealed that these Ply500 formulations were effective in killing L. innocua (a reduced pathogenic surrogate) at challenges up to 100,000 colony-forming units per milliliter both in non-growth-sustaining buffer solution as well as under growth conditions on lettuce. This is a significantly higher concentration of bacteria than is normally found in contaminated food.

"In this study, we have identified a new strategy for selectively killing specific types of bacteria. Stable enzyme-based coatings or sprays could be used in food supply infrastructure—from picking equipment to packaging to preparation—to kill Listeria before anyone has a chance to get sick from it," said contributing author Dr. Ravi Kane, professor of chemical and biological engineering at Rensselaer Polytechnic Institute. "What is most exciting is that we can adapt this technology for all different kinds of harmful or deadly bacteria."

Related Links:
Rensselaer Polytechnic Institute

Print article



view channel
Image: A partially completed three-dimensional printed airway from nostril to trachea with fine structure of the nasal cavity showing (Photo courtesy of Dr. Rui Ni, Pennsylvania State University).

The Structure of the Nasal Cavity Channels Food Smells into the Nose and Avoids the Lungs

Three-dimensional printing technology was used to create a model of the nasal cavity that enabled researchers to demonstrate why the smell of food goes into the nose rather than down into the lungs.... Read more


view channel
Image: Structure of the protein encoded by the CFTR gene (Photo courtesy of Wikimedia Commons).

Advanced Gene Therapy Cures Cystic Fibrosis in Culture and Mouse Models

Improvements in gene therapy technology enabled restoration of ion channel function in cultures of cells from cystic fibrosis (CF) patients and in a CF mouse model. In cystic fibrosis, mutations of... Read more

Lab Technologies

view channel
Image:  The BioSpa 8 Automated Incubator (Photo courtesy of BioTek Instruments).

Smart Incubator System Automates Live Cell Assay Operations

A new instrument that automates laboratory workflow by linking microplate washers and dispensers with readers and imaging systems is now available for biotech and other life sciences researchers.... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.